OTLKNCMHealthcare·Biotechnology#470 in industry

Outlook Therapeutics, Inc.

Reports in 17d· 2026-05-14

-42.7% · 90d

$0.29

-0.03 (-9.55%)

After-Hours $0.29(+0.00)

News

No News Yet

Press releases and SEC filings for OTLK will appear here as they are published.

Check back later for updates

Key Data

Market Cap$34.4M

Open$0.32

Prev Close$0.32

Day Range$0.28 – $0.32

52W Range$0.16 – $3.39

Volume3,819,637

P/E (TTM)—

EPS$-2.89

Dividend Yield—

Beta0.19

Price Target$4.17(+1362.0%)

Next Earnings2026-05-14(17d)

Analyst Ratings

Strong Buy3 analysts

Buy 2Hold 1Sell 0

About

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Healthcare · Biotechnology

17 employees

outlooktherapeutics.com